Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
KEY BENEFITS AND USES
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the patient journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.
PRIMARY MARKET RESEARCH
Survey of ~100 U.S. physicians
Already a Client? Log in to access this report.
Sudha is a Senior Research Associate in the Oncology team at Decision Resources Group. She is responsible for performing secondary market research for major pharmaceutical ; Prior to joining DRG, she obtained her doctorate in life sciences from the National Institute of Immunology, New Delhi, India. She holds a in microbiology and a in biomedical sciences both from the University of Delhi, India and has published several peer-reviewed papers.